Singapore, Mar 18, 2010: Quintiles, a fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide has successfully relocated its Global Central Laboratory in Japan from Saitama to Tokyo to allow for expansion as Quintiles’ business in Japan and Asia-Pacific continues to grow.

The new wholly owned Quintiles facility has expanded testing capabilities with an initial focus on safety testing. The lab started receiving and testing clinical trial samples on March 1, and has already received National Glycohemoglobin Standardization Program Level 1 certification for diabetes testing.

The new Japan lab is taking steps toward certification by the College of American Pathologists (CAP). Quintiles has the largest CAP-certified central laboratory network in the world, with other wholly owned facilities in the US., Europe, South Africa, India, China and Singapore, and a tightly controlled network of affiliate laboratories in Argentina and Brazil. The network recently expanded its anatomical pathology capability in China.

“The growth of clinical research in Asia-Pacific is driving this move as we continue to reduce complexity and help our customers get new medicines to patients faster,” said Alan Ong, Vice President and General Manager, Quintiles Global Central Laboratories Asia. “We are building on a strong record of high quality and outstanding customer service, and with an expanding test menu, it makes sense to move into new facilities that provide room for growth.”